Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17466104 | 0.91 | BRD4 (0.49) | MMP8CA12CA1CA2CA9 | |
| SCHEMBL4064086 | 0.91 | MMP8 (0.51) | MMP8CA12CA1CA2CA9 | |
| SCHEMBL271585 | 0.90 | MMP8 (0.59) | MMP8CA12CA1CA2CA9 | |
| SCHEMBL10727958 | 0.89 | CYP3A4 (0.47) | MMP8CA12CA1CA2CA9 | |
| SCHEMBL9052677 | 0.86 | MMP8 (0.53) | MMP8SMN1; SMN2TSHRALDH1A1TDP1 | |
| SCHEMBL16068663 | 0.85 | ABCB11 (0.43) | MMP8CA12CA1CA2CA9 | |
| SCHEMBL1626467 | 0.85 | CA12 (0.49) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL6444091 | 0.84 | PPARA (0.46) | MMP8CA12CA1CA2CA9 | |
| SCHEMBL7090828 | 0.84 | L3MBTL1 (0.52) | MMP8CA12CA1CA2CA9 | |
| SCHEMBL7093633 | 0.84 | MMP8 (0.52) | MMP8CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364208-B2 | Oxidative coupling of aryl boron reagents with SP3-carbon nucleophiles, and ambient decarboxylative arylation of malonate half-esters via oxidative catalysis | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2019-07-30 | — | — | US | disclosed |
| US-20180186721-A1 | OXIDATIVE COUPLING OF ARYL BORON REAGENTS WITH SP3-CARBON NUCLEOPHILES, AND AMBIENT DECARBOXYLATIVE ARYLATION OF MALONATE HALF-ESTERS VIA OXIDATIVE CATALYSIS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2018-07-05 | — | — | US | disclosed |
| US-20180186721-A1 | OXIDATIVE COUPLING OF ARYL BORON REAGENTS WITH SP3-CARBON NUCLEOPHILES, AND AMBIENT DECARBOXYLATIVE ARYLATION OF MALONATE HALF-ESTERS VIA OXIDATIVE CATALYSIS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2018-07-05 | — | — | US | disclosed |
| EP-3121176-A1 | 2,4-DIAMINOQUINAZOLINES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY | Families of Spinal Muscular Atrophy (US) | 2017-01-25 | — | — | EP | disclosed |
| EP-2275395-B1 | Copper-catalyzed formation of carbon-carbon bonds | MASSACHUSETTS INST TECHNOLOGY (US) | 2016-11-09 | — | — | EP | disclosed |
| EP-1765810-B1 | 2,4-DIAMINOQUINAZOLINES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2514748-B1 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20160152577-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2016-06-02 | — | — | US | disclosed |
| US-9067955-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon—carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067897-B2 | 2,4-Diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2015-06-30 | — | — | US | disclosed |
| US-5777152-A | Process for preparing 2-aryl-2-chloromalonic diesters | HUELS AKTIENGESELLSCHAFT (DE) | 1998-07-07 | — | — | US | disclosed |
| EP-0510526-B1 | Use of sulfonamides as drug and new sulfonamides | HOFFMANN LA ROCHE (CH) | 1996-12-04 | — | — | EP | disclosed |
| EP-0732321-A1 | Process for the preparation of diesters of 2-aryl-2-chloromalonic acid | HÜLS AKTIENGESELLSCHAFT (DE) | 1996-09-18 | — | — | EP | disclosed |
| US-5270313-A | Treatment of circulatory disorders | HOFFMANN-LA ROCHE INC. (US) | 1993-12-14 | — | — | US | disclosed |
| EP-0510526-A1 | Use of sulfonamides as drug and new sulfonamides | F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) | 1992-10-28 | — | — | EP | disclosed |
| EP-0050671-B1 | THIAZOLO(3,2-A)PYRIMIDINE DERIVATIVES, PROCESS FOR PREPARING SAME, AND DRUG CONTAINING SAME | TEIJIN LIMITED (JP) | 1985-03-20 | — | — | EP | disclosed |
| US-4383996-A | IMMUNOREGULATOR | TEIJIN LIMITED (JP) | 1983-05-17 | — | — | US | disclosed |
| EP-0050671-A1 | THIAZOLO(3,2-a)PYRIMIDINE DERIVATIVES, PROCESS FOR PREPARING SAME, AND DRUG CONTAINING SAME | TEIJIN LIMITED (JP) | 1982-05-05 | — | — | EP | disclosed |
| US-4109015-A | PROSTAGLANDINS, LUTEOLYTIC | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1978-08-22 | — | — | US | disclosed |
| US-3984411-A | HYPOCHOLESTEROLEMICS, HYPOGLYCEMICS OR ANTIDIABETICS | SOCIETE GENERALE DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES "SOGERAS" (FR) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152577-A1 | 2,4-Diaminoquinazolines for Spinal Muscular Atrophy | SMN1; SMN2, MUSK, MYO3B | MMP8 3993/4885CA12 4700/4885CA1 4660/4885 |
| US-10364208-B2 | Oxidative coupling of aryl boron reagents with SP3-carbon nucleophiles, and ambient decarboxylative arylation of malonate half-esters via oxidative catalysis | SOD1, AOC3, CBR3 | MMP8 4481/4885CA12 2835/4885CA1 4239/4885 |
| US-20180186721-A1 | OXIDATIVE COUPLING OF ARYL BORON REAGENTS WITH SP3-CARBON NUCLEOPHILES, AND AMBIENT DECARBOXYLATIVE ARYLATION OF MALONATE HALF-ESTERS VIA OXIDATIVE CATALYSIS | SOD1, AOC3, CBR3 | MMP8 4481/4885CA12 2835/4885CA1 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.